Nature Communications (Oct 2020)
Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers
- Sherille D. Bradley,
- Amjad H. Talukder,
- Ivy Lai,
- Rebecca Davis,
- Hector Alvarez,
- Herve Tiriac,
- Minying Zhang,
- Yulun Chiu,
- Brenda Melendez,
- Kyle R. Jackson,
- Arjun Katailiha,
- Heather M. Sonnemann,
- Fenge Li,
- Yaan Kang,
- Na Qiao,
- Bih-Fang Pan,
- Philip L. Lorenzi,
- Mark Hurd,
- Elizabeth A. Mittendorf,
- Christine B. Peterson,
- Milind Javle,
- Christopher Bristow,
- Michael Kim,
- David A. Tuveson,
- David Hawke,
- Scott Kopetz,
- Robert A. Wolff,
- Patrick Hwu,
- Anirban Maitra,
- Jason Roszik,
- Cassian Yee,
- Gregory Lizée
Affiliations
- Sherille D. Bradley
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Amjad H. Talukder
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Ivy Lai
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Rebecca Davis
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Hector Alvarez
- Department of Hematopathology, UT MD Anderson Cancer Center
- Herve Tiriac
- Cold Spring Harbor Laboratory Cancer Center
- Minying Zhang
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Yulun Chiu
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Brenda Melendez
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Kyle R. Jackson
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Arjun Katailiha
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Heather M. Sonnemann
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Fenge Li
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Yaan Kang
- Department of Surgical Oncology, UT MD Anderson Cancer Center
- Na Qiao
- Department of Breast Surgery Research, UT MD Anderson Cancer Center
- Bih-Fang Pan
- Department of Systems Biology, UT MD Anderson Cancer Center
- Philip L. Lorenzi
- Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center
- Mark Hurd
- Ahmed Center for Pancreatic Cancer Research, UT MD Anderson Cancer Center
- Elizabeth A. Mittendorf
- Department of Surgical Oncology, UT MD Anderson Cancer Center
- Christine B. Peterson
- Department of Biostatistics, UT MD Anderson Cancer Center
- Milind Javle
- Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center
- Christopher Bristow
- Center for Co-clinical Trials, UT MD Anderson Cancer Center
- Michael Kim
- Department of Surgical Oncology, UT MD Anderson Cancer Center
- David A. Tuveson
- Cold Spring Harbor Laboratory Cancer Center
- David Hawke
- Department of Systems Biology, UT MD Anderson Cancer Center
- Scott Kopetz
- Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center
- Robert A. Wolff
- Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center
- Patrick Hwu
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Anirban Maitra
- Department of Pathology, UT MD Anderson Cancer Center
- Jason Roszik
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Cassian Yee
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- Gregory Lizée
- Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-020-19141-w
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
Cytotoxic T lymphocyte (CTL)-based immunotherapies can induce tumor regressions by targeting HLA class I-bound tumor-associated peptides. Here, the authors identified a peptide derived from Vestigial-like 1 (VGLL1) as a shared, potentially therapeutic CTL target expressed by multiple cancer types.
